Beximco Pharma begins export of Sotalol to US

Beximco Pharmaceuticals Limited has commenced the export of Sotalol Hydrochloride (80 mg, 120 mg and 160 mg), a generic version of the cardiovascular drug Betapace, to the US, said a statement.
Following the successful launch of Carvedilol to the US in August 2016, this is the second product from Beximco Pharma to be exported to the US.
According to QuintlesIMS data, the market size for Satalol Hydrochloride (including all strengths) in the US is $23 million. The first consignment was delivered on 29 October 2017 and the product will be distributed through the Company's existing partner in the US.
Managing Director of Beximco Pharma, Mr. Nazmul Hassan MP commented: "We are delighted to strengthen our presence in the US with the launch of our second product inthis market. With the export of our first product to the US in August 2016, we began a new era for the pharmaceutical industry in Bangladesh that we continue to build with the launch of Sotalol. Beximco Pharma remains the only Bangladeshi company to export pharmaceutical products to the US, which is a validation of our expertise in offering specialised generic products in a global setting. With our growing pipeline for the US, we will focus on increasingour presence in the world's largest pharma market in the coming years."
In June 2015, Beximco Pharma became the first Bangladeshi pharmaceutical company audited and approved by the US Food and Drug Administration (FDA).